Compounds > efavirenz

efavirenz and Koch's Disease

efavirenz has been researched along with Koch's Disease in 116 studies

Research

Studies (116)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.86)18.2507
2000's27 (23.28)29.6817
2010's67 (57.76)24.3611
2020's21 (18.10)2.80

Authors

AuthorsStudies
Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B1
Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC1
Brun, A; de Castro, N; Hamet, G; Joly, V; Kherabi, Y; Méchaï, F; Molina, JM; Sellier, PO; Yazdanpanah, Y1
Aarnoutse, R; Aber, F; Alinaitwe, L; Buzibye, A; Denti, P; Dooley, KE; Gausi, K; Kengo, A; Lamorde, M; Musaazi, J; Nabisere, R; Najjemba, L; Nampala, J; Omali, D; Otaalo, B; Sekaggya-Wiltshire, C; Sloan, DJ1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z1
Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E1
Aaron, L; Baltrusaitis, K; Chareka, G; Gupta, A; Jean-Philippe, P; Mandima, P; Masheto, G; Mathad, J; McCarthy, K; Montepiedra, G; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Ponatshego, P; Stranix-Chibanda, L1
Brites, C; Chau, GD; Chazallon, C; De Castro, N; Delaugerre, C; Eholié, S; Grinsztejn, B; Khosa, C; Laureillard, D; Marcy, O; Messou, E; Molina, JM; Pilotto, JH; Wittkop, L1
Bottomley, C; Butler, CC; Dorward, J; Garrett, N; Govender, R; Khubone, T; Lessells, RJ; Lewis, L; Maraj, M; Naidoo, K; Phakathi, S; Sookrajh, Y; van der Molen, J; Van Heerden, R1
Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E1
Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H1
Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J1
Aarnoutse, R; Aber, F; Denti, P; Dooley, KE; Lamorde, M; Musaazi, J; Nabisere, R; Sekaggya-Wiltshire, C; Sloan, DJ1
Chishimba, L; Chomba, M; Mbewe, N; Saylor, D; Zimba, S1
Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B1
Aklillu, E; Amogne, W; Burhenne, J; Diczfalusy, U; Habtewold, A; Makonnen, E; Yimer, G; Zumla, A1
Meintjes, G; Pozniak, A1
Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X1
Äbelö, A; Ashton, M; Bienvenu, E; Sundell, J1
Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP1
Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S1
Andrade-Villanueva, J; Caro-Vega, Y; Caylà, J; Crabtree-Ramírez, B; Fehr, J; Girardi, E; Kirk, O; Losso, MH; Lundgren, JD; Miller, RF; Miro, JM; Mocroft, A; Panteleev, A; Podlekareva, DN; Post, FA; Schultze, A; Sierra-Madero, J; Skrahin, A; Tetradov, S; Toibaro, J; W Efsen, AM1
Aklillu, E; Aris, E; Bakari, M; Bertilsson, L; Burhenne, J; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Sandstrom, E1
Buzibye, A; Calcagno, A; Castelnuovo, B; Cusato, J; Fehr, J; Kambugu, A; Lamorde, M; Ledergerber, B; Sekaggya-Wiltshire, C; von Braun, A1
Affolabi, D; Bah-Sow, O; Chirehwa, MT; Denti, P; McIlleron, H; Merle, C; Wiesner, L1
Aklillu, E; Bertilsson, L; Burhenne, J; Janabi, M; Kitabi, EN; Minzi, OMS; Mugusi, F; Mugusi, S; Sasi, P1
do Brasil, PEAA; Hadad, DJ; Maia, IR; Rolla, V; Sant'anna, FM; Schmaltz, CAS; Trajman, A; Xavier, MS1
Beck, IA; Birch, D; Bolton-Moore, C; Bwakura-Dangarembizi, M; Capparelli, E; Chadwick, E; Frenkel, LM; Higa, N; Pelz, A; Samson, P; Sils, T1
Benns, A; Bwakura Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Jackson, C; Jean-Philippe, P; Libous, JL; Moore, CB; Purdue, L; Samson, P; Spector, SA; Wallis, C; Zimmer, B1
Alghamdi, WA; Antwi, S; Dompreh, A; Enimil, A; Kwara, A; Langaee, T; Peloquin, CA; Wiesner, L; Yang, H1
Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM1
Maartens, G1
Aweeka, F; Dooley, KE; Karlsson, MO; Marzan, F; Park, JG; Svensson, EM1
Aweeka, F; Benson, CA; Grinsztejn, B; Havlir, DV; Hogg, E; Ive, P; Lu, D; Luetkemeyer, AF; Marzan, F; Rosenkranz, SL; Sanne, IM; Swindells, S1
Groth, J; Harrison, TS; Macallan, DC; Poulikakos, P; Wake, RM1
Aklillu, E; Gustafsson, LL; Luzze, H; Mukonzo, JK; Nakasujja, N; Ogwal-Okeng, J; Okwera, A; Sebuwufu, D; Waako, P1
Ashton, M; Bienvenu, E; Hoffmann, KJ; Kayumba, PC1
da Silva, TP; Giacoia-Gripp, CB; Morgado, MG; Rolla, V; Sant Anna, FM; Schmaltz, CA1
Bekker, LG; Gupta-Wright, A; Lawn, SD; Wood, R1
Evans, D; Louwagie, G; Okello, V; Takuva, S; Zuma, K1
Ferrand, RA; Ford, N; Pillay, P; Shubber, Z1
Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C1
Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C1
Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S1
Eley, B; Gous, H; Haas, DW; Maartens, G; McIlleron, HM; Merry, C; Moultrie, H; Nuttall, JJ; Ren, Y; Schomaker, M; Sinxadi, P; Smith, P1
Ashton, M; Bienvenu, E; Dandara, C; Swart, M1
Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S1
Chandrasekharan, C; Kumar, AK; Ponnuraja, C; Rajesh, L; Ramachandran, G; Ramesh, K; Swaminathan, S1
Chang, SY; Hung, CC; Kuo, CH; Lee, KY; Lin, SW; Liu, WC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR1
Blanc, FX; Borand, L; Chou, M; Dim, B; Fontanet, A; Goldfeld, AE; Hak, C; Kim, C; Lak, KK; Laureillard, D; Madec, Y; Marcy, O; Nerrienet, E; Pheng, P; Prak, N; Sok, T; Taburet, AM1
Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM1
Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C1
Arya, V; Chan-Tack, KM; Jadhav, P; Kraft, J; Liu, J; Robertson, SM; Seo, S; Singer, ME; Struble, KA1
Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C1
Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN1
Castel, S; Chaisson, RE; Cohn, S; Denti, P; Dooley, KE; Haas, DW; Hoffmann, J; Hull, J; Martinson, N; Mashabela, F; McIlleron, H; Msandiwa, R; Wiesner, L1
Aklillu, E; Bakari, M; Bertilsson, L; Burhenne, J; Diczfalusy, U; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N1
Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM1
Aklillu, E; Gustafson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Waako, P1
Abdool Karim, SS; Botha, JH; Gengiah, TN; Naidoo, K; Yende-Zuma, N1
Grinsztejn, B; Haas, DW; Havlir, DV; Lu, D; Luetkemeyer, AF; McIlleron, H; Rosenkranz, SL; Sanchez, J; Sanne, I; Ssemmanda, M1
Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Yimer, G1
Aris, E; Baernighausen, T; Chalamilla, G; Fawzi, W; Hertzmark, E; Jackson, E; Machumi, L; Muya, A; Mwanyika-Sando, M; Sando, D; Spiegelman, D1
Chonzi, P; Dhoro, M; Kadzirange, G; Masimirembwa, C; Ngara, B; Nhachi, C; Zvada, S1
Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S1
Boucherie, C; Breton, G; Caumes, E; Chaix, ML; Chêne, G; Fagard, C; Lortholary, O; May, T; Molina, JM; Padoin, C; Patey, O; Rami, A; Robert, J; Roussillon, C; Tod, M; Veziris, N1
Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS1
Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Owen, JS; Yimer, G1
Mariana, N; Rusli, A1
Castelnuovo, B; Fehr, J; Kambugu, A; Magambo, B; Scherrer, AU; Sekaggya-Wiltshire, C; von Braun, A1
Naidoo, P; Soorju, V1
Gibbins, S; Kon, O; O'Donoghue, M; Obiorah, I; Sathia, L; Taylor, G; Walsh, J; Winston, A1
Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G1
Boamah, I; Boima, V; Court, MH; Greenblatt, DJ; Kenu, E; Kwara, A; Lartey, M; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Xexemeku, F1
Cabrera, SE; Cordero, M; Domínguez-Gil, A; García, MJ; Iglesias, A; Valverde, MP1
Anitha, S; Gomathi, C; Hemanth Kumar, AK; Kumar, P; Menon, P; Narendran, G; Rajasekaran, S; Ramachandran, G; Ramesh, K; Swaminathan, S1
Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ1
Brouwer, AM; Burger, DM; de Lange, W; van der Ven, A; van Luin, M; van Schaik, RH1
Cilliers, K; Donald, PR; Hussey, GD; Labadarios, D; Maritz, JS; McIlleron, H; Schaaf, HS; Smith, P; Willemse, M1
Lalloo, UG1
Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S1
Hanekom, WA; Maartens, G; Meintjes, G; Rangaka, MX; Seldon, R; Wilkinson, KA; Wilkinson, RJ1
Eampokarap, B; Kaewsaard, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Ruxrungtham, K; Sungkanuparph, S; Suwanvattana, P; Tantanathip, P; Thongyen, S; Uttayamakul, S1
Charalombous, S; Churchyard, G; Cohen, K; Dandara, C; Fielding, K; Grant, A; Maartens, G; McIlleron, H; Pemba, L; Smith, P1
Karunaianantham, R; Narayanan, PR; Rajesh, L; Swaminathan, S1
Kwara, A; Ramachandran, G; Swaminathan, S1
Boima, V; Flanigan, TP; Kenu, E; Kwara, A; Lartey, M; Mingle, JA; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Seshie, M; Wu, H; Xexemeku, F; Yang, H1
Ashton, M; Mukonzo, J; Rekić, D; Röshammar, D1
Cohen, K; Conradie, F; Ive, P; Orrell, C; Sanne, I; Wood, R; Zeinecker, J1
Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W1
Aklillu, E; Bertilsson, L; Burhenne, J; Haefeli, WE; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N1
Fox, D; Mallon, P; McMahon, G; O'Connor, R1
Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P1
Abdool Karim, SS; Botha, JH; Gengiah, TN; Gray, AL; Holford, NH; Naidoo, K1
Aderaye, G; Aklillu, E; Amogne, W; Burhenne, J; Habtewold, A; Lindquist, L; Makonnen, E; Riedel, KD; Suda, A; Ueda, N; Yimer, G1
Aklillu, E; Bakari, M; Janabi, MY; Lindquist, L; Minzi, OM; Mugusi, FM; Mugusi, SF; Ngaimisi, E; Sandstrom, EG; Sasi, PG1
Luaengniyomkul, A; Mankhatitham, W; Manosuthi, W1
Aklillu, E; Bakari, M; Burhenne, J; Janabi, M; Lindquist, L; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sandstrom, E1
Khusmith, S; Likanonsakul, S; Manosuthi, W; Shioda, T; Uttayamakul, S; Wichukchinda, N1
Blanc, FX; Borand, L; Chou, M; Goldfeld, AE; Laureillard, D; Madec, Y; Marcy, O; Pheng, P; Sok, T; Taburet, AM1
Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S1
Bositis, C; Hamangaba, F; Moss, WJ; Sutcliffe, CG; van Dijk, JH; Watson, DC1
Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P1
Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Reynolds, HE; Tija, J1
Cassol, S; El-Sadr, W; Friedland, G; Jack, C; Karim, QA; Karim, SA; Lalloo, U1
Patel, A; Patel, B; Patel, J; Patel, K; Rani, S; Shah, N1
Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L1
Kiertiburanakul, S; Mahanontharit, A; Manosuthi, W; Prasithsirikul, W; Rattanasiri, S; Ruxrungtham, K; Sankote, J; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A1
Brennan-Benson, P; Harrison, T; Lyus, R; Macallan, D; Pakianathan, M1
Benator, D; Burman, W; Engle, M; Khan, A; Peloquin, CA; Vernon, A; Weiner, M; Zhao, Z1
Kiertiburanakul, S; Manosuthi, W; Rattanasiri, S; Ruxrungtham, K; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A1
de Campos, AV; Leon, E; Lopez-Cortes, LF; Lozano, F; Marin-Niebla, A; Marquez-Solero, M; Ruiz-Morales, J; Ruiz-Valderas, R; Valiente, R1
Caligaris, S; Capone, S; Carosi, G; Carvalho, AC; Cusato, M; De Iaco, G; Manfrin, M; Matteelli, A; Regazzi, M; Tomasoni, L; Villani, P1
Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S1
Bartlett, JG1
de Alarcón, A; López-Cortés, LF; Viciana, P1

Reviews

3 review(s) available for efavirenz and Koch's Disease

ArticleYear
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Treatment Outcome; Tuberculosis; Withholding Treatment

2013
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 25

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Coinfection; Cyclopropanes; HIV Infections; Humans; Nevirapine; Rifampin; Treatment Outcome; Tuberculosis; Viral Load

2014
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2010

Trials

47 trial(s) available for efavirenz and Koch's Disease

ArticleYear
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis

2022
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Anti-HIV Agents; Benzoxazines; HIV; HIV Infections; Humans; Rifampin; Tuberculosis

2023
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary

2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
    Contraception, 2023, Volume: 121

    Topics: Adolescent; Benzoxazines; Contraception, Postcoital; Female; HIV Infections; Humans; Levonorgestrel; Rifampin; Tuberculosis

2023
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial.
    BMC pregnancy and childbirth, 2023, Jan-17, Volume: 23, Issue:1

    Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Postpartum Period; Pregnancy; Prevalence; Tuberculosis

2023
Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high tuberculosis burden countries.
    AIDS (London, England), 2023, 10-01, Volume: 37, Issue:12

    Topics: Anti-HIV Agents; HIV Infections; Humans; Raltegravir Potassium; RNA, Viral; Tuberculosis; Viral Load

2023
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Trials, 2020, Feb-13, Volume: 21, Issue:1

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antitubercular Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rifampin; Treatment Outcome; Tuberculosis; Uganda

2020
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
    Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; Benzoxazines; Body Weight; Cyclopropanes; Cytochrome P-450 CYP2B6; Double-Blind Method; Drug Interactions; Equivalence Trials as Topic; Female; Genotype; HIV Infections; Humans; Isoniazid; Metabolic Clearance Rate; Middle Aged; Pregnancy; Prospective Studies; Reverse Transcriptase Inhibitors; Tuberculosis; Young Adult

2021
Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
    British journal of pharmacology, 2021, Volume: 178, Issue:16

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; HIV Infections; Humans; Longitudinal Studies; Rifampin; Tuberculosis

2021
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
    Pharmacogenetics and genomics, 2022, 01-01, Volume: 32, Issue:1

    Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Medroxyprogesterone Acetate; Pharmacogenetics; Rifampin; Tuberculosis

2022
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    BMC infectious diseases, 2017, 12-11, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Tuberculosis; Viral Load

2017
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    The Journal of antimicrobial chemotherapy, 2019, 01-01, Volume: 74, Issue:1

    Topics: Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Inactivation, Metabolic; Isoniazid; Male; Middle Aged; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Young Adult

2019
Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.
    BioMed research international, 2018, Volume: 2018

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rifampin; Tuberculosis

2018
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
    Journal of acquired immune deficiency syndromes (1999), 2019, 08-01, Volume: 81, Issue:4

    Topics: Africa; Alkynes; Benzoxazines; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; India; Infant; Male; Prospective Studies; Treatment Outcome; Tuberculosis

2019
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Mozambique; Nevirapine; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary

2013
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:6

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Diarylquinolines; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Middle Aged; Models, Biological; Quinolines; Stochastic Processes; Treatment Outcome; Tuberculosis; Young Adult

2013
T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytokines; Female; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Male; Mycobacterium; Prospective Studies; Treatment Outcome; Tuberculosis; Viral Load

2013
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
    The Journal of infectious diseases, 2014, Feb-01, Volume: 209, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Benzoxazines; Cambodia; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; HIV Infections; Humans; Isoniazid; Lamivudine; Plasma; Polymorphism, Single Nucleotide; Rifampin; Spectrophotometry, Ultraviolet; Stavudine; Tuberculosis

2014
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:12

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Nevirapine; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Viral Load

2013
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    BMC infectious diseases, 2013, Oct-17, Volume: 13

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; India; Male; Middle Aged; Nevirapine; Pilot Projects; Rifampin; Tuberculosis

2013
Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adult; Alkynes; Benzoxazines; Body Weight; Cambodia; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Tuberculosis

2014
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Young Adult

2014
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:6

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load

2014
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Pharmacogenomics, 2015, Volume: 16, Issue:10

    Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Pharmacogenetics; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2015
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Oct-15, Volume: 61, Issue:8

    Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Isoniazid; Male; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Tuberculosis

2015
Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:12

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Male; Middle Aged; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Young Adult

2016
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:7

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis

2008
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Enzyme Induction; Female; Gene Frequency; Genetic Variation; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2008
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), 2009, Apr-15, Volume: 50, Issue:5

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Linear Models; Male; Rifampin; Tuberculosis; Viral Load

2009
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.
    BMC medicine, 2009, Apr-22, Volume: 7

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; C-Reactive Protein; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Male; Metabolic Clearance Rate; Rifampin; Ritonavir; Tuberculosis

2009
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Plasma; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Treatment Outcome; Tuberculosis; Viral Load

2009
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
    Antiviral therapy, 2009, Volume: 14, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; South Africa; Tuberculosis

2009
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Tuberculosis

2009
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Antiviral therapy, 2011, Volume: 16, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Treatment Outcome; Tuberculosis

2011
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:3

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Liver Function Tests; Logistic Models; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; Thailand; Tuberculosis; Young Adult

2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:3

    Topics: Alkynes; Alleles; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2011
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; India; Liver Function Tests; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Sputum; Treatment Outcome; Tuberculosis; Viral Load

2011
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biotransformation; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Tuberculosis; Young Adult

2012
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:2

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Thailand; Triglycerides; Tuberculosis; Young Adult

2012
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Demography; Haplotypes; HIV Infections; Humans; Incidence; Kaplan-Meier Estimate; Liver; Multivariate Analysis; Pharmacogenetics; Proportional Hazards Models; Risk Factors; Tanzania; Treatment Outcome; Tuberculosis

2012
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
    The Southeast Asian journal of tropical medicine and public health, 2012, Volume: 43, Issue:1

    Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nevirapine; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Rifampin; Thailand; Tuberculosis; Viral Load

2012
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    Clinical pharmacokinetics, 2002, Volume: 41, Issue:9

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Oxazines; Rifampin; Tuberculosis

2002
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.
    Journal of acquired immune deficiency syndromes (1999), 2004, Aug-01, Volume: 36, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Outpatient Clinics, Hospital; Oxazines; Pilot Projects; South Africa; Treatment Outcome; Tuberculosis; Urban Population

2004
Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2004, Sep-01, Volume: 37, Issue:1

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Male; Middle Aged; Oxazines; Rifampin; Treatment Outcome; Tuberculosis

2004
Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
    AIDS (London, England), 2005, Sep-23, Volume: 19, Issue:14

    Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV-1; Humans; Male; Middle Aged; Oxazines; Rifampin; RNA, Viral; Treatment Outcome; Tuberculosis

2005
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    AIDS (London, England), 2006, Jan-02, Volume: 20, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Rifampin; Treatment Outcome; Tuberculosis

2006
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2006

Other Studies

66 other study(ies) available for efavirenz and Koch's Disease

ArticleYear
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
    AIDS (London, England), 2022, 03-15, Volume: 36, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; HIV Infections; Humans; Infant; Tuberculosis

2022
Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
    Journal of acquired immune deficiency syndromes (1999), 2022, 09-01, Volume: 91, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Tuberculosis; Viral Load

2022
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
    The lancet. HIV, 2023, Volume: 10, Issue:5

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Female; HIV Infections; Humans; Male; Pregnancy; Retrospective Studies; South Africa; Tuberculosis; Viral Load

2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
    Pharmacogenetics and genomics, 2023, 08-01, Volume: 33, Issue:6

    Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Contraception, Postcoital; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Isoniazid; Levonorgestrel; Pharmacogenetics; Rifampin; Tuberculosis

2023
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
    PLoS medicine, 2023, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis

2023
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
    Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Availability; CD4 Lymphocyte Count; Chromatography, Liquid; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Female; Genotype; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Sex Factors; Tandem Mass Spectrometry; Tuberculosis; Young Adult

2020
Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir.
    Tropical doctor, 2021, Volume: 51, Issue:2

    Topics: Adult; Alkynes; Benzoxazines; Coinfection; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Hospitals, Teaching; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tuberculosis; Zambia

2021
Raltegravir in patients with tuberculosis.
    The Lancet. Infectious diseases, 2021, Volume: 21, Issue:6

    Topics: Alkynes; Benzoxazines; Coinfection; Cyclopropanes; HIV Infections; Humans; Raltegravir Potassium; Tuberculosis

2021
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
    Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:4

    Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis

2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
    The Journal of antimicrobial chemotherapy, 2021, 10-11, Volume: 76, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Coinfection; Cyclopropanes; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Rifampin; Tandem Mass Spectrometry; Tuberculosis

2021
Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.
    BMC infectious diseases, 2018, 04-23, Volume: 18, Issue:1

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Europe; Europe, Eastern; Female; HIV Infections; Humans; Latin America; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Tuberculosis

2018
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:11

    Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Pharmacogenetics; Prospective Studies; Rifampin; Tuberculosis

2018
High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    The Journal of antimicrobial chemotherapy, 2019, 01-01, Volume: 74, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Serum; Tuberculosis; Uganda; Young Adult

2019
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
    Scientific reports, 2018, 11-05, Volume: 8, Issue:1

    Topics: Adult; Alkynes; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Rifampin; Tanzania; Tissue Distribution; Tuberculosis

2018
Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
    Journal of the Pediatric Infectious Diseases Society, 2020, Apr-30, Volume: 9, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Male; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Tuberculosis

2020
Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
    The Journal of antimicrobial chemotherapy, 2019, 09-01, Volume: 74, Issue:9

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Variation, Individual; Child; Child, Preschool; Coinfection; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; Genotype; HIV Infections; Humans; Male; Models, Theoretical; Pharmacogenomic Testing; Pharmacogenomic Variants; Reverse Transcriptase Inhibitors; Tuberculosis

2019
ART and tuberculosis: the final nail in nevirapine's coffin?
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Tuberculosis

2013
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 57, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Body Weight; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Rifampin; Treatment Outcome; Tuberculosis; Viral Load

2013
Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.
    International journal of STD & AIDS, 2013, Volume: 24, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Monitoring; HIV Infections; Humans; Middle Aged; Mycobacterium; Prospective Studies; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; United Kingdom; Viral Load

2013
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    BMC infectious diseases, 2013, Jun-04, Volume: 13

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cognitive Dysfunction; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Gene Frequency; Hallucinations; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Memory Disorders; Mental Disorders; Prospective Studies; Rifampin; Sleep Arousal Disorders; Tuberculosis; Uganda

2013
A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments.
    Biomedical chromatography : BMC, 2013, Volume: 27, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Female; Humans; Limit of Detection; Male; Reverse Transcriptase Inhibitors; Time Factors; Tuberculosis

2013
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Nevirapine; Risk Factors; South Africa; Stavudine; Time Factors; Tuberculosis; Viral Load

2013
Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    The Pan African medical journal, 2013, Volume: 15

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Eswatini; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Male; Multivariate Analysis; Nevirapine; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Tuberculosis

2013
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    AIDS (London, England), 2013, Jul-31, Volume: 27, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Genotype; HIV Infections; Humans; Male; Plasma; Rifampin; Tuberculosis

2013
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
    Antiviral research, 2014, Volume: 102

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Polymorphism, Single Nucleotide; Rwanda; Tuberculosis; Young Adult

2014
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tuberculosis

2014
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    The Indian journal of medical research, 2013, Volume: 138, Issue:6

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2013
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Body Weight; China; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Drug Therapy, Combination; Ethnicity; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Rifampin; Tuberculosis; Young Adult

2014
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
    International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:6

    Topics: Alkynes; Antibiotics, Antitubercular; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Coinfection; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Approval; Drug Dosage Calculations; Drug Interactions; Genotype; HIV Infections; Humans; Models, Biological; Phenotype; Polypharmacy; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; United States; United States Food and Drug Administration

2014
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
    AIDS (London, England), 2014, Jul-17, Volume: 28, Issue:11

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lymphocyte Activation; Male; Middle Aged; Mycobacterium tuberculosis; Organophosphonates; Risk Factors; Tenofovir; Tuberculosis

2014
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
    The Journal of infectious diseases, 2015, Jan-15, Volume: 211, Issue:2

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Coinfection; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; South Africa; Tuberculosis; Viral Load; Young Adult

2015
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Hydroxycholesterols; Male; Middle Aged; Rifampin; Tuberculosis

2014
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Tolerance; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Treatment Outcome; Tuberculosis

2015
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Pharmacogenomics, 2014, Volume: 15, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Variation; Genotype; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2014
Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
    Antiviral therapy, 2015, Volume: 20, Issue:3

    Topics: Adult; Alkynes; Alleles; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Genotype; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome; Tuberculosis; Young Adult

2015
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jun-15, Volume: 60, Issue:12

    Topics: Alkynes; Antitubercular Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Peru; Pharmacogenetics; Rifampin; South Africa; Tuberculosis; Uganda

2015
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
    BMC infectious diseases, 2015, Mar-26, Volume: 15

    Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Comorbidity; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Male; Nevirapine; Severity of Illness Index; Tanzania; Tuberculosis; Zidovudine

2015
CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    BMC pharmacology & toxicology, 2015, Mar-27, Volume: 16

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Alleles; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; Body Weight; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Hallucinations; Headache; Humans; Male; Models, Biological; Rifampin; Sex Characteristics; Sleep Wake Disorders; Tuberculosis; Zimbabwe

2015
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load

2016
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
    Pharmacogenomics, 2016, Volume: 17, Issue:6

    Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; Viral Load; Zidovudine

2016
Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Acta medica Indonesiana, 2016, Volume: 48, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System; Cyclopropanes; Female; Humans; Male; Middle Aged; Rifampin; Tuberculosis; Viral Load; Young Adult

2016
Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.
    AIDS research and therapy, 2017, Jan-05, Volume: 14, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Treatment Outcome; Tuberculosis; Uganda; Viral Load

2017
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
    African journal of primary health care & family medicine, 2016, Oct-31, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult

2016
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    JAMA, 2008, Aug-06, Volume: 300, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin; South Africa; Treatment Failure; Treatment Outcome; Tuberculosis; Viral Load

2008
Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.
    AIDS (London, England), 2008, Nov-30, Volume: 22, Issue:18

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis

2008
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Geography; HIV Infections; HIV-1; Humans; India; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Rifampin; Tuberculosis

2009
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
    AIDS (London, England), 2009, Mar-27, Volume: 23, Issue:6

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Humans; Male; Middle Aged; Rifampin; Tuberculosis

2009
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Rifampin; Tuberculosis

2009
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
    American journal of respiratory and critical care medicine, 2009, Oct-01, Volume: 180, Issue:7

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; HIV Infections; Humans; Immunization; Lamivudine; Longitudinal Studies; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Stavudine; T-Lymphocytes; Tuberculosis

2009
Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Multivariate Analysis; Rifampin; Tuberculosis

2009
Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Humans; Male; Tuberculosis; Viral Load; Viremia

2011
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
    British journal of clinical pharmacology, 2011, Volume: 71, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Body Weight; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Forecasting; HIV Infections; Humans; Models, Theoretical; Oxidoreductases, N-Demethylating; Phenotype; Rifampin; Tuberculosis

2011
Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.
    Journal of pharmaceutical and biomedical analysis, 2011, Dec-05, Volume: 56, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Drug Stability; HIV Infections; Humans; Reference Standards; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tuberculosis

2011
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biomarkers, Tumor; Case-Control Studies; Comorbidity; Cyclopropanes; Female; Genotype; HIV Infections; Humans; Liver; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Rifampin; Time Factors; Tuberculosis

2011
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.
    Antiviral therapy, 2012, Volume: 17, Issue:2

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Candidiasis, Oral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Karnofsky Performance Status; Leukocyte Count; Male; Middle Aged; Risk Factors; Sarcoma, Kaposi; Tanzania; Tuberculosis

2012
Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.
    Antiviral therapy, 2013, Volume: 18, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Coinfection; Cyclopropanes; HIV Infections; Humans; Tuberculosis; Viral Load

2013
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:2

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult

2013
Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Male; Treatment Failure; Treatment Outcome; Tuberculosis; Viral Load

2013
Simultaneous determination of rifampicin and efavirenz in plasma.
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:5

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; Humans; Male; Middle Aged; Oxazines; Rifampin; Tuberculosis

2002
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
    The Journal of infection, 2006, Volume: 52, Issue:2

    Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis

2006
Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.
    AIDS (London, England), 2005, Sep-23, Volume: 19, Issue:14

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Oxazines; Rifampin; Tuberculosis

2005
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Nov-01, Volume: 41, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Rifabutin; Tuberculosis

2005
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
    Current HIV research, 2007, Volume: 5, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biological Availability; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Prospective Studies; Rifampin; Tuberculosis

2007
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    HIV medicine, 2008, Volume: 9, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Viral Load

2008
Report on HIV/AIDS from IDSA: news from the mile high city.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1999, Volume: 11, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Colorado; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Interleukin-2; Oxazines; Pneumonia, Pneumocystis; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Tuberculosis; United States

1999
Efavirenz plasma concentrations and efficiency.
    AIDS (London, England), 2001, Jun-15, Volume: 15, Issue:9

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Humans; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome; Tuberculosis; Viral Load

2001